Researchers at Karolinska Institutet in Sweden have published new findings in the journal Cancer Discovery showing how pharmacological activation of the protein p53 boosts the immune response against tumours. The results ...
Jul 6, 2021
0
7
Results from a new cell study suggest that the SARS-CoV-2 spike protein can bring about long-term gene expression changes. The findings could help explain why some COVID-19 patients—referred to as COVID long-haulers—experience ...
Apr 27, 2021
0
3
A new study performed in human lung airway cells is one of the first to show a potential link between exposure to organophosphate pesticides and increased susceptibility to COVID-19 infection. The findings could have implications ...
Apr 26, 2021
0
8
Three University of Colorado Cancer Center researchers are part of a team that recently published a paper offering new insight into how the immune system relates to cancer. Quentin Vicens, Ph.D., Jeffrey Kieft, Ph.D., and ...
Mar 19, 2021
0
92
Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term. But the longer-term case burden and the potential for evolution of viral "escape" from immunity will depend on the robustness of immune ...
Mar 9, 2021
1
66
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the ...
Jan 14, 2021
0
31
Pregnant women may be especially vulnerable to developing more severe cases of COVID-19 following SARS-CoV-2 infection, but little is known about their anti-SARS-CoV-2 immune response or how it may affect their offspring. ...
Dec 22, 2020
0
342
The researchers Wasco Wruck and Prof. James Adjaye from the Institute of Stem Cell Research and Regenerative Medicine, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany, employed a bioinformatic approach on ...
Dec 21, 2020
0
6
German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19.
Nov 10, 2020
0
3
Children and adults produce different types and amounts of antibodies in response to infection with the new coronavirus, SARS-CoV-2, a new study from researchers at Columbia University Vagelos College of Physicians and Surgeons ...
Nov 5, 2020
1
451
